Source:http://linkedlifedata.com/resource/pubmed/id/19190817
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-2-4
|
| pubmed:abstractText |
Low-molecular-weight heparins (LMWH) are commonly used as peri-procedural bridging anticoagulants. The usefulness of measurement of anti-factor Xa activity (anti-Xa) to guide bridging therapy with LMWH is unknown. It was the objective of this study to determine levels of anti-Xa during standard bridging therapy with enoxaparin, and to examine predictors for residual anti-Xa. Consecutive patients receiving enoxaparin at a dosage of 1 mg/kg body weight/12 hours for temporary interruption of phenprocoumon were prospectively enrolled to the study. Blood-samples were obtained 14 hours after LMWH-application immediately pre- procedurally. Procedural details, clinical and demographic data were collected and subsequently analyzed. Seventy patients were included (age 75.2 +/- 10.8 years, Cr Cl 55.7 +/- 21.7ml/min, body mass index [BMI] 27.1 +/- 4.9). LMWH- therapy was for a mean of 4.2 +/- 1.6 days; overall anti-Xa was 0.58 +/- 0.32 U/ml. In 37 (52.8%) of patients anti-Xa was > or U/ml, including 10 (14.3%) patients with anti-Xa > 1U/ml. Linear regression analysis of single variables and logistic multivariable regression analysis failed to prove a correlation between anti-Xa and single or combined factors. No major bleeding, no thromboembolism and four (5.7%) minor haemorrhages were observed. When bridging OAC with therapeutic doses of enoxaparin a high percentage of patients undergo interventions with high residual anti-Xa. The levels of anti-Xa vary largely and are independent of single or combined clinical variables. Since the anti-Xa-related outcome of patients receiving bridging therapy with LMWH is not investigated, no firm recommendation on the usefulness of monitoring of anti-Xa can be given at this stage.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0340-6245
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
101
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
325-32
|
| pubmed:meshHeading |
pubmed-meshheading:19190817-Adult,
pubmed-meshheading:19190817-Aged,
pubmed-meshheading:19190817-Aged, 80 and over,
pubmed-meshheading:19190817-Anticoagulants,
pubmed-meshheading:19190817-Drug Administration Schedule,
pubmed-meshheading:19190817-Drug Monitoring,
pubmed-meshheading:19190817-Enoxaparin,
pubmed-meshheading:19190817-Factor Xa,
pubmed-meshheading:19190817-Hemorrhage,
pubmed-meshheading:19190817-Humans,
pubmed-meshheading:19190817-International Normalized Ratio,
pubmed-meshheading:19190817-Linear Models,
pubmed-meshheading:19190817-Logistic Models,
pubmed-meshheading:19190817-Middle Aged,
pubmed-meshheading:19190817-Partial Thromboplastin Time,
pubmed-meshheading:19190817-Phenprocoumon,
pubmed-meshheading:19190817-Pilot Projects,
pubmed-meshheading:19190817-Predictive Value of Tests,
pubmed-meshheading:19190817-Prospective Studies,
pubmed-meshheading:19190817-Risk Assessment,
pubmed-meshheading:19190817-Surgical Procedures, Operative,
pubmed-meshheading:19190817-Thromboembolism,
pubmed-meshheading:19190817-Treatment Outcome
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
|
| pubmed:affiliation |
Department of Internal Medicine/Cardiology, Robert Koch Strasse 1, 53115 Bonn, Germany. ch.hammerstingl@email.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|